An Explorative Study on Calcium Electroporation for Low-risk Basal Cell Carcinoma.
Humans
Carcinoma, Basal Cell
/ pathology
Skin Neoplasms
/ pathology
Male
Female
Middle Aged
Aged
Treatment Outcome
Electrochemotherapy
/ methods
Cell Line, Tumor
Calcium Chloride
/ administration & dosage
Aged, 80 and over
Plasma Membrane Calcium-Transporting ATPases
/ metabolism
Time Factors
Electroporation
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
received:
29
09
2023
accepted:
08
03
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
epublish
Résumé
In electrochemotherapy, permeabilization of the cell membrane by electric pulses increases the anti-tumour effect of chemotherapeutics. In calcium electroporation, chemotherapy is replaced by calcium chloride with obvious benefits. This study explores the effect and underlying mechanisms of calcium electroporation on basal cell carcinomas using either high- or low-frequency electroporation. Low-risk primary basal cell carcinomas were treated in local anaesthesia with intratumoral calcium chloride followed by electroporation with high (167 kHz) or low (5 kHz) frequencies. Non-complete responders were retreated after 3 months. The primary endpoint was tumour response 3 months after last calcium electroporation. Plasma membrane calcium ATPase was examined in various cell lines as plasma membrane calcium ATPase levels have been associated with calcium electroporation efficacy. Twenty-two out of 25 included patients complete the study and 7 of these (32%) achieved complete response at 3 months with no difference in efficacy between high- and low-frequency pulses. High-frequency calcium electroporation was significantly less painful (p=0.03). Plasma membrane calcium ATPase was increased 16-32-fold in basal cell carcinoma cell lines compared with 4 other cancer cell lines. Calcium electroporation for low-risk basal cell carcinomas does not fulfil the requirements of a new dermatological basal cell carcinoma treatment but may be useful as adjuvant treatment to surgery in more advanced basal cell carcinomas. The elevated PMCA levels in basal cell carcinomas may contribute to low efficacy.
Identifiants
pubmed: 38712969
doi: 10.2340/actadv.v104.19678
doi:
Substances chimiques
Calcium Chloride
M4I0D6VV5M
Plasma Membrane Calcium-Transporting ATPases
EC 3.6.3.8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM